Polymorphism in the mTOR promoter is associated with risk of renal cell carcinoma

Jing ZHANG,Lei ZHANG,Shuang LI,Jin-liang LIU,Qiang CAO,Chao QIN,Chang-jun YIN
DOI: https://doi.org/10.3969/j.issn.1009-8291.2015.05.014
2015-01-01
Abstract:ABSTRACT:Objective To explore the association between the polymorphism of mTOR pathway‐related genes and risk of renal cell carcinoma (RCC ) .Methods Eight potentially functional polymorphisms in AKT1 , AKT2 , PTEN and mTOR genes were genotyped using the TaqMan method in a case‐control study of 710 RCC patients and 760 cancer‐free subjects .Un‐conditional logistic regression ,adjusted for potential confounding factors ,was used to assess the risk associations .Results Of the 8 polymorphisms ,after being adjusted for multiple comparisons ,a significant association was found between one variant (rs2295080) in the promoter of mTOR and reduced RCC risk ( P=0 .005 , OR=0 .74 ,95% CI=0 .59 -0 .91 ,TG/GG vs . TT) .Another variant (rs701848) in the 3'UTR region of PTEN was associated with increased RCC risk ( P= 0 .014 , OR=1.45 ,95% CI=1 .08-1 .96 ,CC vs .TT);however ,the association was not significant after being adjusted for multiple com‐parisons .Furthermore ,lower mTOR mRNA levels were observed in the presence of the rs2295080G allele in normal renal tis‐sues .No other significant association between the selected polymorphisms and RCC risk was observed .Conclusion Our re‐sults suggest that the mTOR promoter rs2295080 variant affects RCC susceptibility ,which needs further validation .
What problem does this paper attempt to address?